Therapeutic targeting of C-terminal binding protein in human cancer

Cell Cycle

Volumn 9, Issue 18, 2010, Pages 3764-3774

  Straza, Michael W ^a   Paliwal, Seema ^a   Kovi, Ramesh C ^a   Rajeshkumar, Barur ^a   Trenh, Peter ^a   Parker, Daniel ^a   Whalen, Giles F ^a   Lyle, Stephen ^a   Schiffer, Celia A ^a   Grossman, Steven R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; ARF; Bik; CtBP; Dehydrogenase; MTOB

Indexed keywords

4 METHYLTHIO 2 OXOBUTYRIC ACID; ARF PROTEIN; BINDING PROTEIN; C TERMINAL BINDING PROTEIN 1; C TERMINAL BINDING PROTEIN 2; CELL PROTEIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; PROTEIN BIK; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; GENE TARGETING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PERITONEUM; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION;

EID: 77957003489     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.18.12936     Document Type: Article

References (49)

1. Subramanian T, Chinnadurai G. Association of class I histone deacetylases with transcriptional corepressor CtBP. FEBS Lett 2003; 540:255-8. (Pubitemid 36398067)
2. Chinnadurai G. CtBP family proteins: more than transcriptional corepressors. Bioessays 2003; 25:9-12. (Pubitemid 36093319)
3. Boyd JM, Subramanian T, Schaeper U, La Regina M, Bayley S, Chinnadurai G. A region in the C-terminus of adenovirus 2/5 E1a protein is required for association with a cellular phosphoprotein and important for the negative modulation of T24-ras mediated transformation, tumorigenesis and metastasis. EMBO J 1993; 12:469-78. (Pubitemid 23073693)
4. Schaeper U, Boyd JM, Verma S, Uhlmann E, Subramanian T, Chinnadurai G. Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Proc Natl Acad Sci USA 1995; 92:10467-71.
5. Bergman LM, Blaydes JP. C-terminal binding proteins: emerging roles in cell survival and tumorigenesis. Apoptosis 2006; 11:879-88.
6. Kuppuswamy M, Vijayalingam S, Zhao LJ, Zhou Y, Subramanian T, Ryerse J, et al. Role of the PLDLSbinding cleft region of CtBP1 in recruitment of core and auxiliary components of the corepressor complex. Mol Cell Biol 2008; 28:269-81.
7. Zhang Q, Wang SY, Nottke AC, Rocheleau JV, Piston DW, Goodman RH. Redox sensor CtBP mediates hypoxia-induced tumor cell migration. Proc Natl Acad Sci USA 2006; 103:9029-33. (Pubitemid 43902527)
8. Grooteclaes M, Deveraux Q, Hildebrand J, Zhang Q, Goodman RH, Frisch SM. C-terminal-binding protein corepresses epithelial and proapoptotic gene expression programs. Proc Natl Acad Sci USA 2003; 100:4568-73.
9. Mani-Telang P, Sutrias-Grau M, Williams G, Arnosti DN. Role of NAD binding and catalytic residues in the C-terminal binding protein corepressor. FEBS Lett 2007; 581:5241-6.
10. + and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor. Proc Natl Acad Sci USA 2003; 100:9202-7.
11. Zhang Q, Piston DW, Goodman RH. Regulation of corepressor function by nuclear NADH. Science 2002; 295:1895-7.
12. Thio SS, Bonventre JV, Hsu SI. The CtBP2 co-repressor is regulated by NADH-dependent dimerization and possesses a novel N-terminal repression domain. Nucleic Acids Res 2004; 32:1836-47.
13. Kumar V, Carlson JE, Ohgi KA, Edwards TA, Rose DW, Escalante CR, et al. Transcription corepressor CtBP is an NAD(+)-regulated dehydrogenase. Mol Cell 2002; 10:857-69.
14. Balasubramanian P, Zhao LJ, Chinnadurai G. Nicotinamide adenine dinucleotide stimulates oligomerization, interaction with adenovirus E1A and an intrinsic dehydrogenase activity of CtBP. FEBS Lett 2003; 537:157-60.
15. Kim JH, Youn HD. C-terminal binding protein maintains mitochondrial activities. Cell Death Differ 2009; 16:584-92.
16. Chinnadurai G. The transcriptional corepressor CtBP: a foe of multiple tumor suppressors. Cancer Res 2009; 69:731-4.
17. Arf inhibits the invasion of hepatocellular carcinoma cells by binding to C-terminal binding protein. Cancer Res 2008; 68:476-82.
18. Paliwal S, Kovi RC, Nath B, Chen YW, Lewis BC, Grossman SR. The alternative reading frame tumor suppressor antagonizes hypoxia-induced cancer cell migration via interaction with the COOH-terminal binding protein corepressor. Cancer Res 2007; 67:9322-9.
19. Paliwal S, Pande S, Kovi RC, Sharpless NE, Bardeesy N, Grossman SR. Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis. Mol Cell Biol 2006; 26:2360-72.
20. Mirnezami AH, Campbell SJ, Darley M, Primrose JN, Johnson PW, Blaydes JP. Hdm2 recruits a hypoxia-sensitive corepressor to negatively regulate p53-dependent transcription. Curr Biol 2003; 13:1234-9. (Pubitemid 36872947)
21. INK4A tumor suppressor and senescence in primary human cells. Cancer Res 2008; 68:6049-53.
22. Liu Y, El-Naggar S, Darling DS, Higashi Y, Dean DC. Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development 2008; 135:579-88.
23. Zhang Q, Yoshimatsu Y, Hildebrand J, Frisch SM, Goodman RH. Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell 2003; 115:177-86. (Pubitemid 37329581)
24. Nadauld LD, Phelps R, Moore BC, Eisinger A, Sandoval IT, Chidester S, et al. Adenomatous polyposis coli control of C-terminal binding protein-1 stability regulates expression of intestinal retinol dehydrogenases. J Biol Chem 2006; 281:37828-35.
25. Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai K, et al. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell 2009; 137:623-34.
26. Kovi RC, Paliwal S, Pande S, Grossman SR. An ARF/CtBP2 complex regulates BH3-only gene expression and p53-independent apoptosis. Cell Death Differ 17:513-21.
27. Achouri Y, Noel G, Van Schaftingen E. 2-Keto-4-methylthiobutyrate, an intermediate in the methionine salvage pathway, is a good substrate for CtBP1. Biochem Biophys Res Commun 2007; 352:903-6. (Pubitemid 44894370)
28. Subhi AL, Diegelman P, Porter CW, Tang B, Lu ZJ, Markham GD, et al. Methylthioadenosine phosphorylase regulates ornithine decarboxylase by production of downstream metabolites. J Biol Chem 2003; 278:49868-73.
29. Tang B, Kadariya Y, Murphy ME, Kruger WD. The methionine salvage pathway compound 4-methylthio- 2-oxobutanate causes apoptosis independent of downregulation of ornithine decarboxylase. Biochem Pharmacol 2006; 72:806-15. (Pubitemid 44301049)
30. Walser M. Ketoacids in the treatment of uremia. Clin Nephrol 1975; 3:180-6.
31. Mitch WE, Abras E, Walser M. Long-term effects of a new ketoacid-amino acid supplement in patients with chronic renal failure. Kidney Int 1982; 22:48-53. (Pubitemid 12091217)
32. Dilger RN, Kobler C, Weckbecker C, Hoehler D, Baker DH. 2-keto-4-(methylthio)butyric acid (keto analog of methionine) is a safe and efficacious precursor of L-methionine in chicks. J Nutr 2007; 137:1868-73. (Pubitemid 47292732)
33. Stipanuk MH. The keto acid of methionine is a safe and efficacious substitute for dietary L-methionine: the answer from chick bioassays. J Nutr 2007; 137:1844-5.
34. INK4a genes in colon cancer. Lab Invest 2001; 81:217-29.
35. Chinnadurai G, Vijayalingam S, Rashmi R. BIK, the founding member of the BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic processes. Oncogene 2008; 27:20-9.
36. Daniel PT, Pun KT, Ritschel S, Sturm I, Holler J, Dorken B, et al. Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice. Blood 1999; 94:1100-7. (Pubitemid 29361843)
37. Sturm I, Stephan C, Gillissen B, Siebert R, Janz M, Radetzki S, et al. Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ 2006; 13:619-27.
38. Castells A, Ino Y, Louis DN, Ramesh V, Gusella JF, Rustgi AK. Mapping of a target region of allelic loss to a 0.5 cM interval on chromosome 22q13 in human colorectal cancer. Gastroenterology 1999; 117:831-7. (Pubitemid 29468225)
39. Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F, et al. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 2005; 24:4993-9.
40. Radetzki S, Kohne CH, von Haefen C, Gillissen B, Sturm I, Dorken B, et al. The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines. Oncogene 2002; 21:227-38. (Pubitemid 34102131)
41. Xie X, Xia W, Li Z, Kuo HP, Liu Y, Ding Q, et al. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell 2007; 12:52-65.
42. Zou Y, Peng H, Zhou B, Wen Y, Wang SC, Tsai EM, et al. Systemic tumor suppression by the proapoptotic gene bik. Cancer Res 2002; 62:8-12. (Pubitemid 34073976)
43. Jin W, Scotto KW, Hait WN, Yang JM. Involvement of CtBP1 in the transcriptional activation of the MDR1 gene in human multidrug resistant cancer cells. Biochem Pharmacol 2007; 74:851-9.
44. Walser M, Coulter AW, Dighe S, Crantz FR. The effect of keto-analogues of essential amino acids in severe chronic uremia. J Clin Invest 1973; 52:678-90.
45. Hildebrand JD, Soriano P. Overlapping and unique roles for C-terminal binding protein 1 (CtBP1) and CtBP2 during mouse development. Mol Cell Biol 2002; 22:5296-307.
46. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432:307-15.
47. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497-501.
48. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990; 50:6075-86.
49. Taniguchi T, Garcia-Higuera I, Xu B, Andreassen PR, Gregory RC, Kim ST, et al. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell 2002; 109:459-72.